efixia | Refixia | European Medicines Agency

Keyword	CPC	PCC	Volume	Score	Length of keyword
efixia	1.64	1	4704	29	6

Keyword	CPC	PCC	Volume	Score
affixation	1.61	1	1455	58
efixiate	0.24	0.8	6660	79
affixation definition	0.27	0.4	9059	22
affixation examples	1.5	0.7	3936	8
affixation death	1.82	0.9	5914	49
affixation in english	0.27	0.8	6909	37
affixation words	1.23	0.9	4205	51
affixation in morphology	2	0.5	5282	41
affixation of common seal	1.34	1	2161	46
affixation meaning in urdu	0.44	0.1	3889	93
affixation meaning in death	0.54	0.6	1836	54

Search Results related to efixia on Search Engine

Refixia | European Medicines Agency
europa.eu

https://www.ema.europa.eu/en/medicines/human/EPAR/refixia

WEBAug 2, 2017 · Refixia is a medicine used to treat and prevent bleeding in patients with haemophilia B, an inherited bleeding disorder caused by lack of a clotting protein called factor IX. It can be used in adults and children from 12 years of age. Refixia contains the active substance nonacog beta pegol.

DA: 51 PA: 60 MOZ Rank: 67

Rebinyn (nonacog beta pegol) for hemophilia B | Hemophilia …
hemophilianewstoday.com

https://hemophilianewstoday.com/refixia-n9-gp/

WEBNov 13, 2023 · Indications. Administration. Clinical trials. Side effects. What is Rebinyn for hemophilia? Rebinyn (nonacog beta pegol, or N9-GP) is an extended half-life product approved for treating and preventing bleeds, including those occurring during surgery, in adults and children with hemophilia B.

DA: 85 PA: 54 MOZ Rank: 27

Rebinyn (Nonacog Beta Pegol) - Rare Disease Advisor
rarediseaseadvisor.com

https://www.rarediseaseadvisor.com/therapies/rebinyn-nonacog-beta-pegol/

WEBRebinyn ® (Nonacog beta pegol), also known as Refixia ® in Europe, is a glycopegylated recombinant factor IX protein, with an extended terminal half-life. Conjugation of the protein to a 40-kDa polyethylene glycol (PEG) group slows its removal from the circulation and extends its terminal half-life. The drug is administered intravenously.

DA: 65 PA: 24 MOZ Rank: 46

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
europa.eu

https://www.ema.europa.eu/en/documents/product-information/refixia-epar-product-information_en.pdf

WEBRefixia is a purified recombinant human factor IX (rFIX) with a 40 kDa polyethylene-glycol (PEG) conjugated to the protein. The average molecular weight of Refixia is approximately 98 kDa and the molecular weight of the protein moiety alone is 56 kDa. Upon activation of Refixia, the activation peptide including the 40 kDa polyethylene-glycol ...

DA: 95 PA: 27 MOZ Rank: 54

www.efixia.com
efixia.com

https://www.efixia.com/

WEBWe would like to show you a description here but the site won’t allow us.

DA: 14 PA: 25 MOZ Rank: 9

Nonacog beta pegol (Refixia) for the treatment of hemophilia B
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK487264/

WEBFeb 22, 2018 · Nonacog beta pegol (trade name: Refixia) has been approved in Germany since June 2017 for the treatment of hemophilia B in people over the age of 12. Hemophilia is an inherited disorder that affects the blood's ability to clot.

DA: 75 PA: 14 MOZ Rank: 46

Rebinyn Approved in US as Routine Preventive Hemophilia B
hemophilianewstoday.com

https://hemophilianewstoday.com/news/rebinyn-approved-us-routine-preventive-hemophilia-b-treatment/

WEBAug 10, 2022 · Rebinyn, sold under the brand name Refixia in the EU, is a replacement therapy that had originally been approved in the U.S. as an on-demand treatment to control and treat bleeds, as well as to manage those occurring around the time of surgery in both children and adults with hemophilia B.

DA: 15 PA: 85 MOZ Rank: 30

Refixia (nonacog beta pegol) - European Medicines Agency
europa.eu

https://www.ema.europa.eu/en/documents/overview/refixia-epar-summary-public_en.pdf

WEBRefixia is a medicine used to treat and prevent bleeding in patients with haemophilia B, an inherited bleeding disorder caused by the lack of factor IX, a protein needed to produce blood clots to stop bleeding. Refixia contains the active substance nonacog beta pegol. How is Refixia used?

DA: 89 PA: 45 MOZ Rank: 92

Twitter
twitter.com

https://mobile.twitter.com/efixia

WEBWe would like to show you a description here but the site won’t allow us.

DA: 77 PA: 81 MOZ Rank: 72

Current therapeutic approaches in the management of …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339806/

WEBFeb 15, 2021 · Three EHL FIX proteins have been approved in recent years: recombinant factor IX (Alprolix), extended half-life factor IX (Idelvion) and glycoPEGylated recombinant factor IX (Rebinyn/Refixia). These three products have very different PK profiles due to the specific extravasal distribution of each one.

DA: 24 PA: 4 MOZ Rank: 98